SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

October 2018 Autoimmune News

The effects of methotrexate (MTX) and hydroxychloroquine (HCQ) combination therapy vs methotrexate monotherapy in early rheumatoid arthritis (RA) patients. In contrast to indirect comparison review data, MTX–HCQ seems somewhat more effective after 6 months than MTX monotherapy in early RA patients. PubMed, Rheumatology (Oxford), 2019 Jan 1;58(1):131-134. (Also see Treatments for Rheumatoid Arthritis and DMARDs)

Serum levels of serotonin as a biomarker of newly diagnosed fibromyalgia (FM) in women: Its relation to the platelet indices. This study highlighted that the correction of serum serotonin level by medicines could help the FM patients. PubMed, J Res Med Sci, 2018 Aug 23;23:71. (Also see Fibromyalgia)

Increased Prevalence of Metabolic Syndrome (MetS) and Adipocytokine Levels in a Psoriatic Arthritis(PsA) Cohort. Clinicians caring for PsA patients ought to be aware of the increased risk of MetS in PsA patients, confirmed in different regions worldwide. PubMed, J Clin Rheumatol, 2018 Sep;24(6):302-307. (Also see Psoriasis and Psoriatic Arthritis)

Thymectomy in patients with myasthenia gravis (MG) increases the risk of autoimmune rheumatic diseases (ARDs): a nationwide cohort study. The present nationwide cohort study revealed an association between MG and incident ARDs. PubMed, Rheumatology (Oxford), 2019 Jan 1;58(1):135-143. (Also see Myasthenia Gravis)

Outpatient Engagement Lowers Predicted Risk of Suicide Attempts in Fibromyalgia (FM). This is the first study to successfully apply machine learning to reliably detect suicidality in FM, identifying novel risk factors for suicidality and highlighting outpatient engagement as a protective factor against suicide. PubMed, Arthritis Care Res (Hoboken), 09/07/2018. (Also see Fibromyalgia and Suicide Prevention)

Risk of type 2 diabetes (T2D) and cardiovascular disease in an incident cohort of people with psoriatic arthritis (PsA): A population–based cohort study. The development of T2D in an incident population of PsA is significantly higher than in psoriasis alone, whereas the increased risk of cardiovascular disease in PsA and psoriasis is similar. PubMed, Rheumatology (Oxford), 2019 Jan 1;58(1):144-148. (Also see Psoriasis and Psoriatic Arthritis and Symptoms and Complications of Diabetes)

Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS. PubMed, Ann Rheum Dis, 09/05/2018. (Also see Diagnosis of Lupus and Antiphospholipid Syndrome)

Association between primary Sjögren's syndrome, arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis. Our study suggests that PSS is associated with arterial stiffness and subclinical atherosclerosis. PubMed, Clin Rheumatol, 09/03/2018. (Also see Sjögren's Syndrome)

Long–term patient reported outcomes of elbow, wrist and hand surgery for rheumatoid arthritis (RA). Our original patient–reported outcome assessment tool revealed that elbow, wrist and hand surgery provided long–lasting benefits in RA patients and pain relief was the most favorable effect. PubMed, Int J Rheum Dis, 09/05/2018. (Also see Treatments for Rheumatoid Arthritis)

Interleukin 33 ameliorates disturbance of regulatory T cells in pulmonary sarcoidosis. These results suggested a major anti–inflammatory ability of IL33 to ameliorate the disturbance of Th1/Th2 and Tregs in pulmonary sarcoidosis. PubMed, Int Immunopharmacol, 2018 Sep 6;64:208-216. (Also see Sarcoidosis)


SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA